Oncology Drugs Market by Product Type, End-Users, and Geography (North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa): Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2032

Description

Persistence Market Research provides a thorough analysis of the global Oncology Drugs Market, delivering key insights into market dynamics, growth opportunities, challenges, and evolving trends. This comprehensive study offers an in-depth look at the oncology sector, presenting detailed market analysis and forecasts for the period from 2024 to 2032.

Key Insights:

Oncology Drugs Market Size (2024): USD 224 Billion
Projected Market Value (2032): USD 347.3 Billion
Global Market Growth Rate (CAGR 2024 to 2032): 6.4%

Oncology Drugs Market - Report Scope:

The Oncology Drugs Market encompasses a broad array of pharmaceuticals used in the treatment of cancer. These drugs include chemotherapeutics, targeted therapies, and immunotherapies, each playing a pivotal role in the management of various cancer types. The market caters to oncology departments, cancer research institutes, and healthcare facilities globally, offering advanced therapeutic options to improve patient care and survival rates.

Market Growth Drivers:

Several key factors drive the growth of the global Oncology Drugs Market. The increasing incidence of cancer worldwide, alongside the aging population, significantly contributes to the demand for effective oncology drugs. Innovations in cancer biotechnology, including the development of personalized medicine and biomarker-driven therapies, enhance treatment efficacy and patient outcomes. Furthermore, growing investments in oncology drug research and development by pharmaceutical companies expedite the introduction of novel and more effective cancer treatments.

Market Restraints:

The market faces challenges such as high drug development costs and stringent regulatory frameworks which can delay drug approvals and increase overall expenses. Additionally, the complexity of cancer pathophysiology often leads to varying treatment efficacies across patient populations, posing a hurdle to the universal applicability of certain oncology drugs.

Market Opportunities:

The Oncology Drugs Market presents significant opportunities through the continuous advancement in cancer genomics and molecular biology. Emerging technologies such as CRISPR and next-generation sequencing facilitate the discovery of oncogenes and driving mutations, paving the way for groundbreaking therapies. Expansion into emerging markets with increasing healthcare spending and improving access to medical treatment also provides lucrative prospects for market expansion.

Key Questions Answered in the Report:

What are the primary drivers behind the sustained growth of the global Oncology Drugs Market?
How do recent advancements in cancer research influence the development and adoption of new oncology drugs?
What are the major challenges that stakeholders in the oncology drugs market need to address?
Which regions show the most potential for growth in the oncology drug market?
What strategies are leading companies implementing to foster innovation and improve market share in the oncology sector?

Competitive Intelligence and Business Strategy:

Major players in the global Oncology Drugs Market, including pharmaceutical giants and biotech firms, focus on innovation, regulatory compliance, and global reach to maintain their competitive advantage. These companies heavily invest in R&D to push the boundaries of cancer treatment with newer, more effective drugs. Strategic collaborations with academic institutions and research centers are key to accelerating drug development and achieving regulatory approvals.

Key Companies Profiled:

GlaxoSmithKline
AstraZeneca plc
AbbVie
Pfizer Inc.
Amgen Inc.
Gilead Sciences, Inc.
F.Hoffmann-La Roche Ltd

Oncology Drugs Market Segmentation

By Drug Class:

Chemotherapy

Alkylating Agents

Antimetabolites

Anti-tumour Antibiotics

Topoisomerase Inhibitors

Mitotic Inhibitors

Others

Targeted Therapy

Monoclonal Antibodies

Small molecule Inhibitors

Immunotherapy

Immune Checkpoint Inhibitors.

Cell Therapy and Gene Therapy

Oncolytic Virus Therapy

Immune System Modulators

Others

Hormonal Therapy

By Indication:

Breast Cancer
Lung Cancer
Prostate Cancer
Multiple Myeloma
Colorectal Cancer
Non-Hodgkin's Lymphoma
Kidney Cancer
Chronic lymphocytic Leukaemia
Melanoma
Others

By Route of Administration:

Oral
Injectable

By Distribution Channel:

Hospital Pharmacies
Retail Pharmacies
Others

By Region:

North America
Latin America
Europe
South Asia
East Asia
Oceania
Middle East & Africa

Product Code: PMRREP3312

1. Executive Summary

1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply-Side Trends
1.4. Analysis and Recommendations

2. Market Overview

2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusion and Exclusion

3. Key Market Trends

3.1. Key Trends Impacting the Market
3.2. Product Innovation / Development Trends

4. Key Inclusion

4.1. Key Promotional Strategies, By Manufacturers
4.2. Disease Epidemiology
4.3. Pipeline Assessment
4.4. Regulatory Landscape
4.5. Reimbursement Outlook
4.6. Product Adoption / Usage Analysis
4.7. PESTLE Analysis
4.8. Porter's Analysis

5. Market Background

5.1. Macro-Economic Factors
- 5.1.1. Global GDP Growth Outlook
- 5.1.2. Global Healthcare Industry Market Outlook
- 5.1.3. Pharmaceutical Industry Outlook
5.2. Forecast Factors - Relevance & Impact
- 5.2.1. Rise In Incidence of Cancer
- 5.2.2. Strong Product Pipeline
- 5.2.3. Strategic Developments By Key Players
- 5.2.4. Adoption Of Cell And Gene Therapies
- 5.2.5. Growing Geriatric Population
- 5.2.6. Regulatory Framework
5.3. Market Dynamics
- 5.3.1. Drivers
- 5.3.2. Restraints
- 5.3.3. Opportunity Analysis

6. COVID19 Crisis Analysis

6.1. Impact of COVID-19 - 2024 Market Scenario
6.2. COVID19 and Impact Analysis

7. Global Oncology Drugs Market Demand (in Value US$ Mn) Analysis 2019-2023 and Forecast, 2024-2032

7.1. Historical Market Value (US$ Mn) Analysis, 2019-2023
7.2. Current and Future Market Value (US$ Mn) Projections, 2024-2032
- 7.2.1. Y-o-Y Growth Trend Analysis
- 7.2.2. Absolute $ Opportunity Analysis

8. Global Oncology Drugs Market Analysis 2019-2023 and Forecast 2024-2032, By Drug class

8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ Mn) Analysis By Drug class, 2019-2023
8.3. Current and Future Market Size (US$ Mn) Analysis By Drug class, 2024-2032
- 8.3.1. Chemotherapy
  - 8.3.1.1. Alkylating agents.
  - 8.3.1.2. Antimetabolites.
  - 8.3.1.3. Anti-tumor antibiotics.
  - 8.3.1.4. Topoisomerase inhibitors.
  - 8.3.1.5. Mitotic inhibitors
  - 8.3.1.6. Others
- 8.3.2. Targeted Therapy
  - 8.3.2.1. Monoclonal antibodies
  - 8.3.2.2. Small molecule inhibitors
- 8.3.3. Immunotherapy
  - 8.3.3.1. Immune Checkpoint Inhibitors.
  - 8.3.3.2. Cell Therapy and Gene Therapy
  - 8.3.3.3. Oncolytic Virus Therapy.
  - 8.3.3.4. Cancer Vaccines.
  - 8.3.3.5. Immune System Modulators.
  - 8.3.3.6. Others
- 8.3.4. Hormonal Therapy
8.4. Market Attractiveness Analysis By Drug class

9. Global Oncology Drugs Market Analysis 2019-2023 and Forecast 2024-2032, By Indication

9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Mn) Analysis By Indication, 2019-2023
9.3. Current and Future Market Size (US$ Mn) Analysis Forecast By Indication, 2024-2032
- 9.3.1. Breast Cancer
- 9.3.2. Lung Cancer
- 9.3.3. Prostate Cancer
- 9.3.4. Multiple myeloma
- 9.3.5. Colorectal Cancer
- 9.3.6. Non-Hodgkin's lymphoma
- 9.3.7. Kidney Cancer
- 9.3.8. Chronic lymphocytic leukemia
- 9.3.9. Melanoma
- 9.3.10. Others
9.4. Market Attractiveness Analysis by Indication

10. Global Oncology Drugs Market Analysis 2019-2023 and Forecast 2024-2032, By Route of Administration

10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Mn) Analysis By Route of Administration, 2019-2023
10.3. Current and Future Market Size (US$ Mn) Analysis Forecast By Route of Administration, 2024-2032
- 10.3.1. Oral
- 10.3.2. Injectable
10.4. Market Attractiveness Analysis By Route of Administration

11. Global Oncology Drugs Market Analysis 2019-2023 and Forecast 2024-2032, By Distribution Channel

11.1. Introduction / Key Findings
11.2. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2019-2023
11.3. Current and Future Market Size (US$ Mn) Analysis Forecast By Distribution Channel, 2024-2032
- 11.3.1. Hospital Pharmacies
- 11.3.2. Retail Pharmacies
- 11.3.3. Others
11.4. Market Attractiveness Analysis By Distribution Channel

12. Global Oncology Drugs Market Analysis 2019-2023 and Forecast 2024-2032, by Region

12.1. Introduction
12.2. Historical Market Size (US$ Mn) Analysis by Region, 2019-2023
12.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Region, 2024-2032
- 12.3.1. North America
- 12.3.2. Latin America
- 12.3.3. Europe
- 12.3.4. South Asia
- 12.3.5. East Asia
- 12.3.6. Oceania
- 12.3.7. Middle East & Africa(MEA)
12.4. Market Attractiveness Analysis by Region

13. North America Oncology Drugs Market Analysis 2019-2023 and Forecast 2024-2032

13.1. Introduction
13.2. Historical Market Size (US$ Mn) by Market Taxonomy, 2019-2023
13.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Market Taxonomy, 2024-2032
- 13.3.1. By Country
  - 13.3.1.1. U.S.
  - 13.3.1.2. Canada
- 13.3.2. By Drug class
- 13.3.3. By Indication
- 13.3.4. By Route of Administration
- 13.3.5. By Distribution Channel
13.4. Market Attractiveness Analysis
- 13.4.1. By Country
- 13.4.2. By Drug class
- 13.4.3. By Indication
- 13.4.4. By Route of Administration
- 13.4.5. By Distribution Channel
13.5. Market Trends
13.6. Key Market Participants - Intensity Mapping
13.7. Drivers and Restraints - Impact Analysis
13.8. Country Level Analysis & Forecast
- 13.8.1. U.S. Oncology Drugs Market
  - 13.8.1.1. Introduction
  - 13.8.1.2. Market Analysis and Forecast by Market Taxonomy
    - 13.8.1.2.1. By Drug class
    - 13.8.1.2.2. By Indication
    - 13.8.1.2.3. By Route of Administration
    - 13.8.1.2.4. By Distribution Channel
- 13.8.2. Canada Oncology Drugs Market
  - 13.8.2.1. Introduction
  - 13.8.2.2. Market Analysis and Forecast by Market Taxonomy
    - 13.8.2.2.1. By Drug class
    - 13.8.2.2.2. By Indication
    - 13.8.2.2.3. By Route of Administration
    - 13.8.2.2.4. By Distribution Channel

14. Latin America Oncology Drugs Market Analysis 2019-2023 and Forecast 2024-2032

14.1. Introduction
14.2. Historical Market Size (US$ Mn) Analysis by Market Taxonomy, 2019-2023
14.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Market Taxonomy, 2024-2032
- 14.3.1. By Country
  - 14.3.1.1. Brazil
  - 14.3.1.2. Mexico
  - 14.3.1.3. Argentina
  - 14.3.1.4. Rest of Latin America
- 14.3.2. By Drug class
- 14.3.3. By Indication
- 14.3.4. By Route of Administration
- 14.3.5. By Distribution Channel
14.4. Market Attractiveness Analysis
- 14.4.1. By Country
- 14.4.2. By Drug class
- 14.4.3. By Indication
- 14.4.4. By Route of Administration
- 14.4.5. By Distribution Channel
14.5. Market Trends
14.6. Key Market Participants - Intensity Mapping
14.7. Drivers and Restraints - Impact Analysis
14.8. Country Level Analysis & Forecast
- 14.8.1. Brazil Oncology Drugs Market
  - 14.8.1.1. Introduction
  - 14.8.1.2. Market Analysis and Forecast by Market Taxonomy
    - 14.8.1.2.1. By Drug class
    - 14.8.1.2.2. By Indication
    - 14.8.1.2.3. By Route of Administration
    - 14.8.1.2.4. By Distribution Channel
- 14.8.2. Mexico Oncology Drugs Market
  - 14.8.2.1. Introduction
  - 14.8.2.2. Market Analysis and Forecast by Market Taxonomy
    - 14.8.2.2.1. By Drug class
    - 14.8.2.2.2. By Indication
    - 14.8.2.2.3. By Route of Administration
    - 14.8.2.2.4. By Distribution Channel
- 14.8.3. Argentina Oncology Drugs Market
  - 14.8.3.1. Introduction
  - 14.8.3.2. Market Analysis and Forecast by Market Taxonomy
    - 14.8.3.2.1. By Drug class
    - 14.8.3.2.2. By Indication
    - 14.8.3.2.3. By Route of Administration
    - 14.8.3.2.4. By Distribution Channel

15. Europe Oncology Drugs Market Analysis 2019-2023 and Forecast 2024-2032

15.1. Introduction
15.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
15.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2024-2032
- 15.3.1. By Country
  - 15.3.1.1. Germany
  - 15.3.1.2. Italy
  - 15.3.1.3. France
  - 15.3.1.4. U.K.
  - 15.3.1.5. Spain
  - 15.3.1.6. BENELUX
  - 15.3.1.7. Russia
  - 15.3.1.8. Rest of Europe
- 15.3.2. By Drug class
- 15.3.3. By Indication
- 15.3.4. By Route of Administration
- 15.3.5. By Distribution Channel
15.4. Market Attractiveness Analysis
- 15.4.1. By Country
- 15.4.2. By Drug class
- 15.4.3. By Indication
- 15.4.4. By Route of Administration
- 15.4.5. By Distribution Channel
15.5. Market Trends
15.6. Key Market Participants - Intensity Mapping
15.7. Drivers and Restraints - Impact Analysis
15.8. Country Level Analysis & Forecast
- 15.8.1. Germany Oncology Drugs Market
  - 15.8.1.1. Introduction
  - 15.8.1.2. Market Analysis and Forecast by Market Taxonomy
    - 15.8.1.2.1. By Drug class
    - 15.8.1.2.2. By Indication
    - 15.8.1.2.3. By Route of Administration
    - 15.8.1.2.4. By Distribution Channel
- 15.8.2. Italy Oncology Drugs Market
  - 15.8.2.1. Introduction
  - 15.8.2.2. Market Analysis and Forecast by Market Taxonomy
    - 15.8.2.2.1. By Drug class
    - 15.8.2.2.2. By Indication
    - 15.8.2.2.3. By Route of Administration
    - 15.8.2.2.4. By Distribution Channel
- 15.8.3. France Oncology Drugs Market
  - 15.8.3.1. Introduction
  - 15.8.3.2. Market Analysis and Forecast by Market Taxonomy
    - 15.8.3.2.1. By Drug class
    - 15.8.3.2.2. By Indication
    - 15.8.3.2.3. By Route of Administration
    - 15.8.3.2.4. By Distribution Channel
- 15.8.4. U.K. Oncology Drugs Market
  - 15.8.4.1. Introduction
  - 15.8.4.2. Market Analysis and Forecast by Market Taxonomy
    - 15.8.4.2.1. By Drug class
    - 15.8.4.2.2. By Indication
    - 15.8.4.2.3. By Route of Administration
    - 15.8.4.2.4. By Distribution Channel
- 15.8.5. Spain Oncology Drugs Market
  - 15.8.5.1. Introduction
  - 15.8.5.2. Market Analysis and Forecast by Market Taxonomy
    - 15.8.5.2.1. By Drug class
    - 15.8.5.2.2. By Indication
    - 15.8.5.2.3. By Route of Administration
    - 15.8.5.2.4. By Distribution Channel
- 15.8.6. BENELUX Oncology Drugs Market
  - 15.8.6.1. Introduction
  - 15.8.6.2. Market Analysis and Forecast by Market Taxonomy
    - 15.8.6.2.1. By Drug class
    - 15.8.6.2.2. By Indication
    - 15.8.6.2.3. By Route of Administration
    - 15.8.6.2.4. By Distribution Channel
- 15.8.7. Russia Oncology Drugs Market
  - 15.8.7.1. Introduction
  - 15.8.7.2. Market Analysis and Forecast by Market Taxonomy
    - 15.8.7.2.1. By Drug class
    - 15.8.7.2.2. By Indication
    - 15.8.7.2.3. By Route of Administration
    - 15.8.7.2.4. By Distribution Channel

16. South Asia Oncology Drugs Market Analysis 2019-2023 and Forecast 2024-2032

16.1. Introduction
16.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
16.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2024-2032
- 16.3.1. By Country
  - 16.3.1.1. India
  - 16.3.1.2. Thailand
  - 16.3.1.3. Indonesia
  - 16.3.1.4. Malaysia
  - 16.3.1.5. Rest of South Asia
- 16.3.2. By Drug class
- 16.3.3. By Indication
- 16.3.4. By Route of Administration
- 16.3.5. By Distribution Channel
16.4. Market Attractiveness Analysis
- 16.4.1. By Country
- 16.4.2. By Drug class
- 16.4.3. By Indication
- 16.4.4. By Route of Administration
- 16.4.5. By Distribution Channel
16.5. Market Trends
16.6. Key Market Participants - Intensity Mapping
16.7. Drivers and Restraints - Impact Analysis
16.8. Country Level Analysis & Forecast
- 16.8.1. India Oncology Drugs Market
  - 16.8.1.1. Introduction
  - 16.8.1.2. Market Analysis and Forecast by Market Taxonomy
    - 16.8.1.2.1. By Drug class
    - 16.8.1.2.2. By Indication
    - 16.8.1.2.3. By Route of Administration
    - 16.8.1.2.4. By Distribution Channel
- 16.8.2. Thailand Oncology Drugs Market
  - 16.8.2.1. Introduction
  - 16.8.2.2. Market Analysis and Forecast by Market Taxonomy
    - 16.8.2.2.1. By Drug class
    - 16.8.2.2.2. By Indication
    - 16.8.2.2.3. By Route of Administration
    - 16.8.2.2.4. By Distribution Channel
- 16.8.3. Indonesia Oncology Drugs Market
  - 16.8.3.1. Introduction
  - 16.8.3.2. Market Analysis and Forecast by Market Taxonomy
    - 16.8.3.2.1. By Drug class
    - 16.8.3.2.2. By Indication
    - 16.8.3.2.3. By Route of Administration
    - 16.8.3.2.4. By Distribution Channel
- 16.8.4. Malaysia Oncology Drugs Market
  - 16.8.4.1. Introduction
  - 16.8.4.2. Market Analysis and Forecast by Market Taxonomy
    - 16.8.4.2.1. By Drug class
    - 16.8.4.2.2. By Indication
    - 16.8.4.2.3. By Route of Administration
    - 16.8.4.2.4. By Distribution Channel

17. East Asia Oncology Drugs Market Analysis 2019-2023 and Forecast 2024-2032

17.1. Introduction
17.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
17.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2024-2032
- 17.3.1. By Country
  - 17.3.1.1. China
  - 17.3.1.2. Japan
  - 17.3.1.3. South Korea
- 17.3.2. By Drug class
- 17.3.3. By Indication
- 17.3.4. By Route of Administration
- 17.3.5. By Distribution Channel
17.4. Market Attractiveness Analysis
- 17.4.1. By Country
- 17.4.2. By Drug class
- 17.4.3. By Indication
- 17.4.4. By Route of Administration
- 17.4.5. By Distribution Channel
17.5. Market Trends
17.6. Key Market Participants - Intensity Mapping
17.7. Drivers and Restraints - Impact Analysis
17.8. Country Level Analysis & Forecast
- 17.8.1. China Oncology Drugs Market
  - 17.8.1.1. Introduction
  - 17.8.1.2. Market Analysis and Forecast by Market Taxonomy
    - 17.8.1.2.1. By Drug class
    - 17.8.1.2.2. By Indication
    - 17.8.1.2.3. By Route of Administration
    - 17.8.1.2.4. By Distribution Channel
- 17.8.2. Japan Oncology Drugs Market
  - 17.8.2.1. Introduction
  - 17.8.2.2. Market Analysis and Forecast by Market Taxonomy
    - 17.8.2.2.1. By Drug class
    - 17.8.2.2.2. By Indication
    - 17.8.2.2.3. By Route of Administration
    - 17.8.2.2.4. By Distribution Channel
- 17.8.3. South Korea Oncology Drugs Market
  - 17.8.3.1. Introduction
  - 17.8.3.2. Market Analysis and Forecast by Market Taxonomy
    - 17.8.3.2.1. By Drug class
    - 17.8.3.2.2. By Indication
    - 17.8.3.2.3. By Route of Administration
    - 17.8.3.2.4. By Distribution Channel

18. Oceania Oncology Drugs Market Analysis 2019-2023 and Forecast 2024-2032

18.1. Introduction
18.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
18.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2024-2032
- 18.3.1. By Country
  - 18.3.1.1. Australia
  - 18.3.1.2. New Zealand
- 18.3.2. B By Drug class
- 18.3.3. By Indication
- 18.3.4. By Route of Administration
- 18.3.5. By Distribution Channel
18.4. Market Attractiveness Analysis
- 18.4.1. By Country
- 18.4.2. By Drug class
- 18.4.3. By Indication
- 18.4.4. By Route of Administration
- 18.4.5. By Distribution Channel
18.5. Country Level Analysis & Forecast
- 18.5.1. Australia Oncology Drugs Market
  - 18.5.1.1. Introduction
  - 18.5.1.2. Market Analysis and Forecast by Market Taxonomy
    - 18.5.1.2.1. By Drug class
    - 18.5.1.2.2. By Indication
    - 18.5.1.2.3. By Route of Administration
    - 18.5.1.2.4. By Distribution Channel
- 18.5.2. New Zealand Oncology Drugs Market
  - 18.5.2.1. Introduction
  - 18.5.2.2. Market Analysis and Forecast by Market Taxonomy
    - 18.5.2.2.1. By Drug class
    - 18.5.2.2.2. By Indication
    - 18.5.2.2.3. By Route of Administration
    - 18.5.2.2.4. By Distribution Channel

19. MEA Oncology Drugs Market Analysis 2019-2023and Forecast 2024-2032

19.1. Introduction
19.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
19.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2024-2032
- 19.3.1. By Country
  - 19.3.1.1. GCC Countries
  - 19.3.1.2. Turkey
  - 19.3.1.3. South Africa
  - 19.3.1.4. North Africa
  - 19.3.1.5. Rest of MEA
- 19.3.2. By Drug class
- 19.3.3. By Indication
- 19.3.4. By Route of Administration
- 19.3.5. By Distribution Channel
19.4. Market Attractiveness Analysis
- 19.4.1. By Country
- 19.4.2. By Drug class
- 19.4.3. By Indication
- 19.4.4. By Route of Administration
- 19.4.5. By Distribution Channel
19.5. Market Trends
19.6. Key Market Participants - Intensity Mapping
19.7. Drivers and Restraints - Impact Analysis
19.8. Country Level Analysis & Forecast
- 19.8.1. GCC Countries Oncology Drugs Market
  - 19.8.1.1. Introduction
  - 19.8.1.2. Market Analysis and Forecast by Market Taxonomy
    - 19.8.1.2.1. By Drug class
    - 19.8.1.2.2. By Indication
    - 19.8.1.2.3. By Route of Administration
    - 19.8.1.2.4. By Distribution Channel
- 19.8.2. Turkey Oncology Drugs Market
  - 19.8.2.1. Introduction
  - 19.8.2.2. Market Analysis and Forecast by Market Taxonomy
    - 19.8.2.2.1. By Drug class
    - 19.8.2.2.2. By Indication
    - 19.8.2.2.3. By Route of Administration
    - 19.8.2.2.4. By Distribution Channel
- 19.8.3. South Africa Oncology Drugs Market
  - 19.8.3.1. Introduction
  - 19.8.3.2. Market Analysis and Forecast by Market Taxonomy
    - 19.8.3.2.1. By Drug class
    - 19.8.3.2.2. By Indication
    - 19.8.3.2.3. By Route of Administration
    - 19.8.3.2.4. By Distribution Channel
- 19.8.4. North Africa Oncology Drugs Market
  - 19.8.4.1. Introduction
  - 19.8.4.2. Market Analysis and Forecast by Market Taxonomy
    - 19.8.4.2.1. By Drug class
    - 19.8.4.2.2. By Indication
    - 19.8.4.2.3. By Route of Administration
    - 19.8.4.2.4. By Distribution Channel

20. Market Structure Analysis

20.1. Market Analysis by Tier of Companies
20.2. Market Share Analysis of Top Players

21. Competition Analysis

21.1. Competition Dashboard
21.2. Competition Benchmarking
21.3. Competition Deep Dive (Tentative List)
- 21.3.1. GlaxoSmithKline plc.
  - 21.3.1.1. Overview
  - 21.3.1.2. Product Portfolio
  - 21.3.1.3. SWOT Analysis
  - 21.3.1.4. Strategy Overview
    - 21.3.1.4.1. Marketing Strategies
    - 21.3.1.4.2. Product Strategies
    - 21.3.1.4.3. Channel Strategies
- 21.3.2. Astrazeneca
  - 21.3.2.1. Overview
  - 21.3.2.2. Product Portfolio
  - 21.3.2.3. SWOT Analysis
  - 21.3.2.4. Strategy Overview
    - 21.3.2.4.1. Marketing Strategies
    - 21.3.2.4.2. Product Strategies
    - 21.3.2.4.3. Channel Strategies
- 21.3.3. Merck KGaA
  - 21.3.3.1. Overview
  - 21.3.3.2. Product Portfolio
  - 21.3.3.3. SWOT Analysis
  - 21.3.3.4. Strategy Overview
    - 21.3.3.4.1. Marketing Strategies
    - 21.3.3.4.2. Product Strategies
    - 21.3.3.4.3. Channel Strategies
- 21.3.4. Johnson & Johnson
  - 21.3.4.1. Overview
  - 21.3.4.2. Product Portfolio
  - 21.3.4.3. SWOT Analysis
  - 21.3.4.4. Strategy Overview
    - 21.3.4.4.1. Marketing Strategies
    - 21.3.4.4.2. Product Strategies
    - 21.3.4.4.3. Channel Strategies
- 21.3.5. Pfizer, Inc.
  - 21.3.5.1. Overview
  - 21.3.5.2. Product Portfolio
  - 21.3.5.3. SWOT Analysis
  - 21.3.5.4. Strategy Overview
    - 21.3.5.4.1. Marketing Strategies
    - 21.3.5.4.2. Product Strategies
    - 21.3.5.4.3. Channel Strategies
- 21.3.6. Bayer AG
  - 21.3.6.1. Overview
  - 21.3.6.2. Product Portfolio
  - 21.3.6.3. SWOT Analysis
  - 21.3.6.4. Strategy Overview
    - 21.3.6.4.1. Marketing Strategies
    - 21.3.6.4.2. Product Strategies
    - 21.3.6.4.3. Channel Strategies
- 21.3.7. Sanofi S.A.
  - 21.3.7.1. Overview
  - 21.3.7.2. Product Portfolio
  - 21.3.7.3. SWOT Analysis
  - 21.3.7.4. Strategy Overview
    - 21.3.7.4.1. Marketing Strategies
    - 21.3.7.4.2. Product Strategies
    - 21.3.7.4.3. Channel Strategies
- 21.3.8. Boehringer Ingelheim
  - 21.3.8.1. Overview
  - 21.3.8.2. Product Portfolio
  - 21.3.8.3. SWOT Analysis
  - 21.3.8.4. Strategy Overview
    - 21.3.8.4.1. Marketing Strategies
    - 21.3.8.4.2. Product Strategies
    - 21.3.8.4.3. Channel Strategies
- 21.3.9. Bausch Health Companies Inc.
  - 21.3.9.1. Overview
  - 21.3.9.2. Product Portfolio
  - 21.3.9.3. SWOT Analysis
  - 21.3.9.4. Strategy Overview
    - 21.3.9.4.1. Marketing Strategies
    - 21.3.9.4.2. Product Strategies
    - 21.3.9.4.3. Channel Strategies
- 21.3.10. Galderma SA
  - 21.3.10.1. Overview
  - 21.3.10.2. Product Portfolio
  - 21.3.10.3. SWOT Analysis
  - 21.3.10.4. Strategy Overview
    - 21.3.10.4.1. Marketing Strategies
    - 21.3.10.4.2. Product Strategies
    - 21.3.10.4.3. Channel Strategies
- 21.3.11. Novartis AG (Alcon)
  - 21.3.11.1. Overview
  - 21.3.11.2. Product Portfolio
  - 21.3.11.3. SWOT Analysis
  - 21.3.11.4. Strategy Overview
    - 21.3.11.4.1. Marketing Strategies
    - 21.3.11.4.2. Product Strategies
    - 21.3.11.4.3. Channel Strategies
- 21.3.12. Arbor Pharmaceuticals
  - 21.3.12.1. Overview
  - 21.3.12.2. Product Portfolio
  - 21.3.12.3. SWOT Analysis
  - 21.3.12.4. Strategy Overview
    - 21.3.12.4.1. Marketing Strategies
    - 21.3.12.4.2. Product Strategies
    - 21.3.12.4.3. Channel Strategies
- 21.3.13. Perrigo Company Plc.
  - 21.3.13.1. Overview
  - 21.3.13.2. Product Portfolio
  - 21.3.13.3. SWOT Analysis
  - 21.3.13.4. Strategy Overview
    - 21.3.13.4.1. Marketing Strategies
    - 21.3.13.4.2. Product Strategies
    - 21.3.13.4.3. Channel Strategies
- 21.3.14. Allergan
  - 21.3.14.1. Overview
  - 21.3.14.2. Product Portfolio
  - 21.3.14.3. SWOT Analysis
  - 21.3.14.4. Strategy Overview
    - 21.3.14.4.1. Marketing Strategies
    - 21.3.14.4.2. Product Strategies
    - 21.3.14.4.3. Channel Strategies
- 21.3.15. Lupin
  - 21.3.15.1. Overview
  - 21.3.15.2. Product Portfolio
  - 21.3.15.3. SWOT Analysis
  - 21.3.15.4. Strategy Overview
    - 21.3.15.4.1. Marketing Strategies
    - 21.3.15.4.2. Product Strategies
    - 21.3.15.4.3. Channel Strategies
- 21.3.16. Teva pharmaceuticals
  - 21.3.16.1. Overview
  - 21.3.16.2. Product Portfolio
  - 21.3.16.3. SWOT Analysis
  - 21.3.16.4. Strategy Overview
    - 21.3.16.4.1. Marketing Strategies
    - 21.3.16.4.2. Product Strategies
    - 21.3.16.4.3. Channel Strategies
- 21.3.17. Ultragenyx Pharmaceutical Inc
  - 21.3.17.1. Overview
  - 21.3.17.2. Product Portfolio
  - 21.3.17.3. SWOT Analysis
  - 21.3.17.4. Strategy Overview
    - 21.3.17.4.1. Marketing Strategies
    - 21.3.17.4.2. Product Strategies
    - 21.3.17.4.3. Channel Strategies
- 21.3.18. Zydus Cadila Healthcare Ltd.
  - 21.3.18.1. Overview
  - 21.3.18.2. Product Portfolio
  - 21.3.18.3. SWOT Analysis
  - 21.3.18.4. Strategy Overview
    - 21.3.18.4.1. Marketing Strategies
    - 21.3.18.4.2. Product Strategies
    - 21.3.18.4.3. Channel Strategies
- 21.3.19. Glenmark Pharmaceuticals
  - 21.3.19.1. Overview
  - 21.3.19.2. Product Portfolio
  - 21.3.19.3. SWOT Analysis
  - 21.3.19.4. Strategy Overview
    - 21.3.19.4.1. Marketing Strategies
    - 21.3.19.4.2. Product Strategies
    - 21.3.19.4.3. Channel Strategies